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Comparison of Programmed Stimulation and Holter Monitoring for
Predicting Long-Term Efficacy and Inefficacy of Amiodarone Used
Alone or in Combination With a Class lA Antiarrhythmic Agent in
Patients With Ventricular Tachyarrhythmia
SOO G. KIM, MD, FACC, SAMUEL D. FELDER, MD, ILONA FIGURA, MD,
DEBRA R. JOHNSTON, RN, LAWRENCE E. WASPE, MD, FACC, JOHN D. FISHER, MD, FACC
Bronx. New York
The values of two Holter ambulatory electrocardio-
graphic monitoring criteria and one programmed stim-
ulation efficacycriterion reported to be predictive of the
efficacy of amiodarone were compared in 70 patients
taking amiodarone for sustained ventricular tachyar-
rhythmias. At baseline, all patients had ventricular
tachycardia inducible by programmed stimulation. After
amiodarone loading (935 ± 271 mg for 16 ± 7 days),
efficacy was determined by a programmed stimulation
criterion (ventricular tachycardia no longer inducible or
:sIS beats) and two Holter monitoring criteria (Holter
I = 2':85% reduction of ventricular premature com-
plexesand abolition of couplets and triplets in 64 patients
who had 2': 10 ventricular premature complexes/hor cou-
plets or triplets or both before therapy; Holter II =
abolition of triplets in 41 patients who had triplets before
therapy). Amiodarone was effective in 12 of 70 patients
by the programmed stimulation criterion, in 49 of 64
patients by Holter criterion I and in 37 of 41 patients
by Holter criterion II. In assessing efficacy of amioda-
rone, programmed stimulation and Holter criteria were
discordant in 69% of patients or more (p < 0.001).
There were 16 recurrences or sudden deaths during
the entire follow-up period (19 ± 19 months). Arrhyth-
mia-free survival rates at 24 months of patients with
efficacy and inefficacy by each criterion, respectively,
The roleof programmed stimulation in assessing theefficacy
and inefficacy of amiodarone therapy in patients with ma-
lignantventriculararrhythmia is controversial (I-II). Many
investigators (1-7) have reported poor predictive values of
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were 90 and 78% by programmed stimulation, 84 and
62% by Holter criterion I (p < 0.05) and 73 and 50%
by Holter criterion II (p < 0.05). At 24 months, sensi-
tivities of programmed stimulation and Holter I and II
criteria were 92,42 and 18%, respectively; specificities
were 17, 86 and 94%, respectively, and predictive ac-
curacies were 43,71 and 63%, respectively. In patients
with discordance between Holter monitoring and pro-
grammed stimulation findings, the specificity of pro-
grammed stimulation was less than 10% and the sen-
sitivity of Holter monitoring was less than 20% at 12
months.
Conclusions: 1) Treatment with amiodarone in a sig-
nificant number of patients cannot be managed by Holter
monitoring. 2) Inefficacyby Holter criteria predicts poor
outcome but efficacy does not preclude poor outcome
(insensitive). 3) Inefficacy by programmed stimulation
does not preclude good outcome (nonspecific). 4) Many
patients have inefficacy by programmed stimulation de-
spite efficacy by Holter criteria; this is due to both in-
sensitivity of Holter monitoring and nonspecificity of
programmed stimulation. 5) Further studies should be
conducted to identify predictors of efficacy of amloda-
rone in patients with discordant results.
(J Am Coll Cardiol1987;9:398-404)
programmed stimulation in patients taking amiodarone,
whereas others (8-11) have reportedthat programmed stim-
ulation is predictive in such patients. Holter ambulatory
electrocardiographic monitoring hasalso been usedto assess
the efficacy and inefficacy of amiodarone (6,11-15); some
investigators (6,12-14) have reported that it yields good
predictive valuesin patients takingamiodarone whereasoth-
ers (II, 15)havereportedpoorpredictive values. No studies,
however, have compared the predictive values of pro-
grammed stimulation and Holter monitoring in the same
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patients. It is unknown, therefore, which method is more
predictive in assessing the efficacy of amiodarone.
To compare the predictive values of Holter monitoring
and programmed stimulation, we used concurrent Holter
monitoring and programmed stimulation in 70 patients tak-
ing amiodarone for recurrent sustained ventricular tachy-
cardia or ventricular fibrillation. Efficacy of amiodarone in
each patient was determined by Holter monitoring and pro-
grammed stimulation criteria, Sensitivity, specificity and
positive and negative predictive values and predictive ac-
curacy of various efficacy criteria were compared in the
same patients.
Methods
Study patients. Seventy patients (54 male, 16 female;
mean age 61 ± 10 years; 50 with coronary artery disease,
20 with cardiomyopathy) with recurrent sustained ventric-
ular tachycardia with hemodynamic compromise (66 pa-
tients) or ventricular fibrillation (4 patients) were studied.
The mean number of episodes of ventricular tachyarrhyth-
mia was 2.7 ± 1.0. None of the arrhythmias were associated
with acute myocardial infarction or remediable causes (such
as hypokalemia, digitalis toxicity or drug-induced arrhyth-
mia). Criteria for admission to the study also included an
inducible sustained ventricular tachycardia by programmed
stimulation requiring intervention for termination during a
baseline study in the absence of antiarrhythmic agents, Pa-
tients with arrhythmias refractory to conventional nonex-
peri mental drugs and mexiletine or patients with intolerable
side effects from conventional drugs and mexiletine were
entered into this study.
Programmed ventricular stimulation. The pro-
grammed stimulation protocol used in this study has been
published (16). Single (S2), double (S2S3) or triple (S2S,S4)
premature stimuli were introduced during sinus rhythm (SISI)
initially, and then during ventricular pacing (SI SI) at cycle
lengths of 600 to 400 ms. The end point of the stimulation
was I) induction of a sustained ventricular tachycardia that
required intervention for termination, or 2) completion of
the stimulation protocol. Amiodarone was considered ef-
fective by programmed stimulation when ventricular tachy-
cardia was no longer inducible or nonsustained (-S:15 beats)
(10).
Ambulatory electrocardiographic monitoring. The
detailed methods and accuracy and reproducibility of am-
bulatory monitoring used in this study have been published
(17). Two Holter monitoring efficacy criteria reported to be
predictive (13,14) were used in this study, Amiodarone was
considered effective when it resulted in I) 85% or greater
reduction of ventricular premature complexes and abolition
of couplets and nonsustained ventricular tachycardia (2: 3
ventricular premature complexes at a rate of > 100/min) in
patients who had frequent (2: 10/h) ventricular premature
complexes or any couplets or nonsustained ventricular
tachycardia on baseline Holter monitoring (Holter criterion
I) (\ 3); or 2) abolition of nonsustained ventricular tachy-
cardia in patients who had nonsustained ventricular tachy-
cardia on baseline Holter monitoring (Holter criterion II)
(14).
Study design. Informed consent was obtained from all
patients before the study for serial drug testing by pro-
grammed stimulation and ambulatory electrocardiographic
monitoring and administration of amiodarone. All patients
had a baseline 24 hour ambulatory electrocardiogram and
programmed stimulation study at least five half-lives after
discontinuation of all antiarrhythmic medications. Amio-
darone was given orally twice daily in equally divided doses.
All patients received a loading dose of amiodarone (935 ±
271 mg/day) for 16 ± 7 days followed by a maintenance
dose of 356 ± 109 mg/day. In the beginning of the study,
the loading doses ranged between 600 and 800 mg/day.
Currently, all patients receive a loading dose of I ,200 mg/day
of amiodarone for 14 days, All patients remained hospital-
ized during the loading period. Programmed stimulation and
Holter monitoring were repeated at the end of amiodarone
loading. In 18 patients with a hemodynamically significant
ventricular tachycardia inducible by programmed stimula-
tion on amiodarone, a class IA conventional antiarrhythmic
agent (quinidine, procainamide or disopyramide) was added
and programmed stimulation and Holter monitoring were
repeated before discharge from the hospital.
The end point offollow-up ofthis retrospective study was
I) recurrence of symptomatic sustained ventricular tachy-
cardia or sudden death, 2) death due to other causes, 3)
discontinuation of the discharge regimen because of side
effects, or 4) arrhythmia-free survival as of February 15,
1986.
Statistical methods. Standard deviation (mean ± SD)
was used as the index of dispersion of observed values. The
Kaplan-Meier method was used to generate actuarial sur-
vival rates of each group. The differences between groups
were tested by the log rank test for statistical significance.
A two-tailed probability (p) value of less than 0.05 was
considered significant. The definition of sensitivity, speci-
ficity, positive and negative predictive values and predictive
accuracy are shown in Table I.
Results
Programmed ventricular stimulation (Table 2). At
baseline before therapy, all 70 patients, including four pa-
tients whose documented arrhythmia was ventricular fibril-
lation, had a sustained monomorphic ventricular tachycardia
induced by programmed stimulation requiring intervention
for termination, Twenty-nine patients required one to two
extrastimuli for induction of ventricular tachycardia, 12 pa-
tients required three extrastimuli during sinus rhythm and
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Table 3. Results of Holter Electrocardiographic Monitoring in
20 Patients
Table 1. Definitions
Sensitivity
Specificity
Positive predictive value
Negative predictive value
Predictive accuracy
TP/(TP + FN)
TN/(TN + FP)
TP/(TP + FP)
TN/(TN + FN)
(TP + TN)/total population
No. of VPCs/h
No. of couplets/h
No. of VT episodes/24 h
Baseline
436 ± 472
7 ± 18
65 ± 163
Amiodarone
72 ± 188
0.1 ± 0.5
6 ± 15
Table 2. Results of Programmed Stimulation in 20 Patients
PES = programmed extrastimulus; SR = sinus rhythm; VP = ven-
tricular pacing; VT = ventricular tachycardia.
FN = false negative(patientswithefficacyby programmed stimulation
or Holter criteria but with subsequent clinical arrhythmic events); FP =
false positive (patients with inefficacy by these criteria but no clinical
arrhythmic events); TN = true negative (patients with efficacy by these
criteria and no clinical arrhythmic events); TP = true positive (patients
with inefficacy by these criteria and clinical arrhythmicevents).
29 patients required three extrastimuli during ventricular
pacing.
Holter electrocardiographic monitoring (Table 3). At
baseline, 41 patients had nonsustained ventricular tachy-
cardia with or without couplets or 10 or more ventricular
premature complexes/h (group A), 23 patients had no non-
sustained ventricular tachycardia but couplets or 10or more
ventricular premature complexes/h (group B) and 6 patients
had infrequent « IO/h) ventricular premature complexes
without couplets or nonsustained ventricular tachycardia
(group C).
By Holter criterion I (See Methods for definition), 64
(groups A and B) of the 70 patients (91%) qualified for
Holter assessment of amiodarone therapy with frequent
(2: IO/h) or complex ventricular premature complexes, or
both, on baseline Holter monitoring. By Holter criterion II,
41 (group A) of 70 patients (59%) qualified for Holter as-
sessment of amiodarone therapy with nonsustained ventric-
ular tachycardia on baseline Holter monitoring. Six patients
(group C) did not qualify for Holter assessment by the cri-
teria used in this study.
Efficacy assessments by programmed stimulation and
Holter criteria. Efficacy of amiodarone in each patient was
assessed by programmed stimulation and Holter criteria.
Amiodarone was effective in 12 patients and ineffective in
58 by the programmed stimulation criterion, effective in 49
of 64 patients and ineffective in 15 by Holter criterion I and
VPCs = ventricular premature complexes; VT = nonsustained ven-
tricular tachycardia.
effective in 37 of 41 patients and ineffective in 4 by Holter
criterion II.
Correlation between programmed stimulation and
Holter monitoring in assessing efficacy of amiodarone
(Table 4). Efficacy assessments by Holter criterion I (64
patients) and Holter criterion II (41 patients) were compared
with the efficacy assessments by the programmed stimula-
tion criterion. It was unusual for a patient to have both
persistence of spontaneous ventricular ectopic activity on
Holter monitoring and suppression of inducible tachycardia.
Many patients, however, had a suppression of spontaneous
ventricular ectopic activity with a persistent induction of
ventricular tachycardia (discordance between Holter mon-
itoring and programmed stimulation). Holter criterion I and
programmed stimulation criterion were discordant in as-
sessing efficacy of amiodarone in 44 (69%) of 64 patients
(p < 0.001 by McNemar's test). Holter criterion II and
programmed stimulation criterion were discordant in 32 (78%)
of 41 patients (p < 0.001). The majority (>93%) of in-
stances of discordance occurred because amiodarone therapy
was assessed effective by the Holter criteria but ineffective
by the programmed stimulation criterion, suggesting insen-
sitivity (false efficacy) of Holter monitoring criteria or non-
specificity (false inefficacy) of programmed stimulation cri-
terion, or both.
Results of follow-up. The mean duration of follow-up
was 19.2 ± 19.3 months (mean ± SD, SE = 2.3) in all
patients. There were 16 recurrences or sudden deaths, 10
nonarrhythmic cardiac deaths and 4 deaths due to noncardiac
causes during the entire follow-up period.
Arrhythmia-free survival rates were generated by the
Kaplan-Meier method and the differences were tested by
the log rank test (Table 5). Patients with efficacy by the
programmed stimulation criterion seemed to have a better
prognosis compared with patients with inefficacy by this
criterion, especially during the first 6 months of follow-up.
The differences, however, did not reach statistical signifi-
cance. Patients with inefficacy by Holter criterion I or II
had a poor prognosis compared with patients with efficacy
by these criteria.
From the results offollow-up, sensitivity, specificity, pos-
itive predictive value, negative predictive value and pre-
dictive accuracy of each criterion were generated (Table
6). In brief, programmed stimulation criterion had a high
2
2
II
7
18
18
12
Posttreatment
(No.)
o
4
12
6
19
29
Pretreatment
(No.)
VT induction by
SR + 1 PES
SR + 2 PES
SR + 3 PES
VP + I PES
VP + 2 PES
VP + 3 PES
No VT inducible
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Table 4. Correlation Between Efficacy Assessments by Holter Monitoring and Programmed
Stimulation Criteria in 20 Patients
Concordant
Effective by both
Ineffective by both
Discordant
Effective only by Holter monitoring
Effective only by PES
Discordance by McNemar's test
PES versus Holler I
(n = 64)
8 (13%)
12 (19%)
41 (64°k)
3 (5%)
P < 0.001
PES versus Holter II
(0 = 41)
6 (15)
3(7)
31 (76)
1(2%)
P < 0.001
Holter I = Holter monitoring criterion I; Holter II = Holter monitoring criterion II; PES = programmed
extrastimulation.
sensitivity, high negativepredictivevalue but low specificity
(high false inefficacyrate) and low positive predictivevalue.
Holter criteria I and II had low sensitivities (high false
efficacy rate) but high specificities, Positive predictive val-
ues of Holter criteria were higher than that of programmed
stimulation. Predictive accuracies of Holter criteria I and II
were better than those of programmed stimulation but were
73% or less.
Results offollow-up of patients with discordant efficacy
assessments by Holter and programmed stimulation criteria
were analyzed. From the results of follow-up at 12 months,
the sensitivity and specificity of each criterion in patients
with discordant results were obtained (Table 7). The dis-
cordance between Holter monitoring and programmedstim-
ulation in assessing efficacy of amiodarone was due to both
nonspecificity (false efficacy) of programmed stimulation
and insensitivity (false efficacy) of Holter monitoring.
Discussion
Our study suggests that in patients taking amiodarone:
I) positive Holter monitoring (inefficacy) predicts a poor
outcome but is insensitive; 2) positive programmed stimu-
lation is nonspecific and does not preclude a good outcome;
and 3) the discordance between programmed stimulation
and Holter monitoring is due to both insensitivity of Holter
monitoring and nonspecificity of programmed stimulation.
Efficacy criteria for assessing results of amiodarone
therapy. Among the major problems in comparing the re-
sultsof Holter monitoringand programmedstimulationfrom
various studies (10, 13,14) are differences in patient selec-
tion, efficacy criteria, duration and amount of amiodarone
dosing before assessing efficacy and duration of follow-up.
In this study, we have attemptedto overcomethese problems
by applying various efficacy criteria to the same patient
population.
Programmed stimulation protocol. Our programmed
stimulation protocol, patient selection criteria based on the
programmed stimulation results at baseline and efficacycri-
terion used in this study are the same as those of other
investigators (10).
Holter monitoring protocol. The Holter monitoring ef-
ficacy criteria I and II used in our study, including patient
selection criteria, are the same criteria used in two studies
(13,14) that reported good predictive values of Holter mon-
itoring in patients taking amiodarone.
The study protocol. The mean loading dose and main-
tenance dose of amiodarone in this study and our timing of
programmed stimulation and Holter monitoring during
amiodarone therapy are similar to those of other studies
Table 5. Arrhythmia-Free Survival Rates by Various Efficacy Criteria
Months
6 12 18 24 P Value
Effective by PES (n = 12) (%) 100 90 90 90 p = 0.2150Ineffective by PES (n = 58) (%) 81 78 78 78
Effective by Holter I (n = 49) (%) 87 84 84 84
P = 0.0340Ineffective by Holter I (n = IS) (%) 70 62 62 62
Effective by Holter II (n = 37) (%) 80 73 73 73
P = 0.0180Ineffective by Holter II (n = 4) (%) SO SO SO SO
Holter I and II = Holter monitoring criteria I and II; PES = programmed stimulation criteria.
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Table 6. Predictive Values of Various Criteria
Negat ive
Positive Predictive Pred ictive Value Pred ictive
Sensitivity (%) Specificity (%) Value (% ) (% ) Accuracy (% )
24 rna All 24 rna All 24 rna All 24 rna All 24 rna All
PES 92 94 17 20 37 35 80 92 43 37
Holler I 42 38 86 8 1 63 40 73 80 7 1 70
Holter II 18 23 94 96 67 75 63 73 63 73
All = entire follow-up period; other abbreviations as in Table 4 . See Method s for explanations .
(10,1 3,14). Amiodarone was a sole antiarrhythmic agent in
two of these studies (13,14). Other antiarrhythmic agents
were added in another study (10) and in our study. The
duration of follow-up and the end points of follow-up in
this study are similar to those of other studies.
Data analysis and statistical methods. Different statis-
tical methods were used in previous studies (10, 13, 14),
making it difficult to compare the results of various studies
(18). To avoid the problem, we analyzed our data by the
same statistical methods used in other studies and compared
the values of Holter monitoring and programmed stimula-
tion.
Comparison of various criteria. More patients qualified
for the assessment by Holter monitoring criterion I than by
criterion II (91 versus 59%). The sensitivity of Holter cri-
terion I was better than that of Holter criterion II. Because
a low sensitivity and limited applicability are major limi-
tations of Holter monitoring, one might state that Holter
criterion I appears to be better than Holter criterion II.
Patients with efficacy by programm ed stimulation, 17%
of all patients studied, appeared to have a better prognosis
compared with patients with inefficacy, although the dif-
ference did not reach statistical significance. The difference
may become significant in a study of a larger patient pop-
ulation. Inefficacy by programmed stimulation, however,
did not preclude a good outcome in many patients (non-
specifi city of programmed stimulation). This finding has
been reported by many investigators (1- 9, II ).
Comparison of results of this study and other studies.
Many patients in our study required three extrastimuli for
induction of ventricular tachycardia at baseline. This may
have been due to our stimulation protocol calling for three
extrastimuli during sinus rhythm before one or two extras-
timuli during ventricular pacing. Had we used only one or
two extrastimuli, the sensitivity and specificity of pro-
grammed stimulation might have been different from those
reported in this study.
Efficacy rates in this study were similar to those of other
studies . Horowitz et al. (10) reported that 20 (20%) of 100
patients had suppression of inducible ventricular tachycardia
with amiodarone as compared with 12 ( 17%) of 70 patients
in our study. Marchlinski et al. (13) reported that 34 (62%)
of 55 patients had efficacy by theircriterion (Holtercriterion
I) as compared with 49 (77%) of 64 patients in our study.
Veltri et al. (14) reported that 34 (8 1%) of 42 patients had
efficacy by their criterion (Holter criterion II) as compared
with 37 (90%) of 4 1 patients in our study. The results of
follow-up of all patients in our study are somewhat better
than those of others (10) but within the range of those in
previously reported studies (1,3,4-6, 15). These find ings
may suggest that our study population and methods are
probably similar to those of other studies.
Many investigators have evaluated Holter monitoring in
patients with 30 or more ventricular premature complexes/h
at baseline (19-22). Marchlinski et al. (13), however, used
a less stringent qualification criterion (2::10 ventricular pre-
mature complexes/h) with a very good reported predictive
value. For this reason, we used their criterion in this study.
Amiodarone versus other antiarrhythmic agents . We have
previously reported that programmed stimulation and Holter
Table 7. The Results of Follow-Up in Patients With a Discordance Between Holter Monitoring
and Programmed Stimulation
Programmed Stimulation Holter Mon itoring
Discordance
PES versus
Holter I (n = 44)
Holter II ( n = 32)
Sensitivity
(%)
100
100
Specificity
(%)
8
6
Sensitivity
( %)
o
o
Specifici ty
(%)
92
94
n = number of patient s with discordant results. Results of follow-up at 12 month s are shown. Results
during the en tire follow-up period were similar to the results shown here.
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monitoring are discordant in assessing efficacy of class I A
agents (16) and mexiletine (23). From those studies, we
postulated that the discordance may be due to insensitivity
of Holter monitoring criteria or nonspecificity of the pro-
grammed stimulation criterion, or both. This postulation
was based on the observation that in the majority of instances
of discordance, a therapy was considered effective by a
Holter criterion but ineffective by a programmed stimulation
criterion (16,23). A similar relation (discordance) between
Holter monitoring and programmed stimulation was noted
in the present study of patients taking amiodarone. There-
fore, the discordance between Holter monitoring and pro-
grammed stimulation in patients taking other antiarrhythmic
agents may also be due to both insensitivity of Holter mon-
itoring and nonspecificity of programmed stimulation. This
assumption remains to be tested.
Limitations of this study. the relatively small number
of patients in our study is a limitation. Other studies (10,13,14)
claiming the value of Holter monitoring or programmed
stimulation, however, had the same limitations. Whereas
Horowitz et al. (10) studied 100 patients, Marchlinski et al.
(13) studied 55 patients and Veltri et al. (14) studied 42
patients, An additional antiarrhythmic agent taken by some
patients is another limitation. Other investigators (10), how-
ever, also used an additional antiarrhythmic agent.
Clinical implications andconclusions. This study sug-
gests: I) treatment with amiodarone in a significant number
of patients cannot be managed by Holter monitoring because
of a lack of ambient ectopic activity; these patients require
programmed stimulation for efficacy assessment of amio-
darone. 2) Patients with inefficacy by Holter monitoring
criteria usually have inefficacy by programmed stimulation.
They have a poor outcome; therefore, they should receive
other therapies. 3) Efficacy by Holter monitoring, however,
may not preclude a poor outcome (insensitivity of Holter
monitoring); patients with efficacy by Holter criteria, there-
fore, should probably be evaluated by programmed stimu-
lation. 4) Efficacy by programmed stimulation predicts a
favorable outcome, 5) Inefficacy by the programmed stim-
ulation criterion, especially in patients with efficacy by Hol-
ter criteria, may not preclude a good clinical outcome (non-
specificity of programmed stimulation). 6) Many patients
have inefficacy by programmed stimulation despite efficacy
by Holter monitoring (discordance). Because the discor-
dance is due to the combination of insensitivity of Holter
monitoring and nonspecificity of programmed stimulation,
it is problematical. Considering the malignant nature of
recurrences, one could argue that we should rely more heav-
ily on the results of programmed stimulation with a high
sensitivity (low false efficacy) at the expense of specificity
(false inefficacy). This argument may be valid if alternative
therapies for these patients (some with false inefficacy) have
a low morbidity and mortality and are easily available. The
issue, however, will remain problematic until better pre-
dictors of efficacy of amiodarone are found. 7) Further stud-
ies should be done to identify the predictor of recurrence
of arrhythmia in such patients with discordant results.
We express our appreciation to Patti Garcia for secretarial assistance in
the manuscript preparation.
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